Previous studies have shown that Regorafenib inhibited TGF-β1-induced EMT in colorectal cancer by activating SHP-1-dependent P-STAT3 by directly dephosphorylating STAT3 on Tyr705 thus silencing the downstream pathway in in vivo and in vitro 2D models [62]. The gene discussed is STAT3; the disease is colorectal cancer.